 
MAINE STATE LEGISLATURE  
 
 
 
The following document is provided by the 
LAW AND LEGISLATIVE DIGITAL LIBRARY  
at the Maine State Law and Legislative Reference Library 
http://legislature.m aine.gov/lawlib 
 
 
 
 
 
 
 
 
 
 
Reproduced from electronic originals 
(may include minor formatting diffe rences from printed original) 
 
 
Printed on recycled paper128th MAINE LEGISLATURE
FIRST REGULAR SESSION-2017
Legislative Document No. 952
S.P. 307 In Senate,  March  9, 2017
An Act  To Ensure Access  to Opiate Addiction Treatment in Maine
Reference to the Committee on Health  and Human Services suggested and  ordered printed.
HEATHER  J.R. PRIEST
Secretary of the Senate
Presented by Senator WOODSOME of York.
Cosponsored by Representative POULIOT of Augusta and
Senators: BREEN of  Cumberland, CUSHING of Penobscot, DION of Cumberland, 
GRATWICK of Penobscot,  LANGLEY of Hancock, Representatives: BATTLE of South 
Portland, HARVELL  of Farmington, VACHON of Scarborough.

 
 Page 1 - 128LR1530(01) -1 
 Be it enacted by the People of the State of Maine as follows:  1 
Sec. 1.  32 MRSA §2211 is enacted to read:  2 
§2211.  Dispensing opioid medication to patients in opioid treatment programs  3 
A registered professional nurse and a certified nurse practitioner may di spense opioid 4 
medication for substance abuse treatment purposes to patients within an opioid treatment 5 
program under the direction of the medical director of the opioid treatment program.  6 
Sec. 2.  32 MRSA §2258 -B is enacted to read:  7 
§2258 -B.  Dispensing op ioid medication to patients in opioid treatment programs  8 
A licensed practical nurse may dispense opioid medication for substance abuse 9 
treatment purposes to patients within an opioid treatment program under the direction of 10 
the medical director of the opio id treatment program.  11 
Sec. 3.  32 MRSA §13751, sub -§5 is enacted to read:  12 
5.  Opioid treatment program; pharmacist oversight of take -home medication 13 
dispensing.  An opioid treatment program under rules adopted by the board is not 14 
required to maintain a pha rmacist in charge to be responsible for the opioid treatment 15 
program's compliance with this chapter, rules adopted by the board and federal and state 16 
laws, rules and regulations specified in board rules.  An opioid treatment program shall 17 
enter into a writ ten agreement with a licensed pharmacist to serve as a consultant on the 18 
dispensing of opioid medication to patients for take -home use.  The consultant pharmacist 19 
shall visit the opioid treatment program at least once a month to review the 20 
pharmaceutical s ervices and monitor the services to ensure accuracy and prepare a report 21 
including findings and recommendations for improvement.  The opioid treatment 22 
program shall maintain on site signed and dated reports for each on -site visit by the 23 
consultant pharmaci st.  The consultant pharmacist shall develop procedures for the 24 
distribution and controls of drugs and biologicals in the opioid treatment program; 25 
compound, package, label and dispense all drugs to be administered to clients; inspect all 26 
areas where drugs  are stored, including, but not limited to, emergency supplies, to ensure 27 
that all drugs are properly labeled, stored and controlled; and monitor drug therapy for 28 
drug interactions and incompatibilities and maintain documentation of the drug 29 
interactions a nd incompatibilities.  The opioid treatment program in consultation with the 30 
consultant pharmacist shall develop and implement written policies and procedures for 31 
control and accountability, distribution and assurance of quality of all drugs and 32 
biological s.  The opioid treatment program shall maintain records for all transactions of 33 
pharmaceutical services as required by law and as necessary to maintain control of, and 34 
accountability for, all drugs and pharmaceutical supplies.  The dispensing of opioids fo r 35 
take-home use by an opioid treatment program may be undertaken by any professional 36 
whose scope of practice permits such dispensing.  The board shall adopt rules to 37 
implement this subsection.  Rules adopted pursuant to this subsection are routine 38 
technica l rules as defined in Title 5, chapter 375, subchapter 2 -A. 39 
 
 Page 2 - 128LR1530(01) -1 
 Sec. 4.  MaineCare reimbursement rates for outpatient opioid treatment.  1 
The Department of Health and Human Services shall amend its rule Chapter 101: 2 
MaineCare Benefits Manual, Chapter III, Secti on 65, Behavioral Health Services 3 
regarding the reimbursement rate paid to outpatient opioid treatment providers to increase 4 
the rate from $60 to $80 a week. The department may amend its rules to increase the rates 5 
above the reimbursement rates specified i n this section at any time. The department shall 6 
take all necessary actions to implement the reimbursement increase under this section.  7 
Sec. 5.  Rate study.  The Department of Health and Human Services shall contract 8 
with a 3rd -party consultant to conduct a rate study regarding the reimbursement rate paid 9 
to outpatient opioid treatment providers under its rule Chapter 101: MaineCare Benefits 10 
Manual, Chapter III, Section 65, Behavioral Health Services. The rate study must account 11 
for provider costs related t o outpatient opioid treatment services. The department shall 12 
ensure that the 3rd -party consultant conducting the study under this section invites the 13 
participation of stakeholders providing outpatient opioid treatment services. The 14 
department shall report its progress and findings under this section to the Joint Standing 15 
Committee on Health and Human Services no later than December 30, 2017. The 16 
committee may report out a bill related to the report to the Second Regular Session of the 17 
128th Legislature.  18 
Sec. 6.  Outpatient opioid treatment providers opening days.  The office of 19 
substance abuse and mental health services, division of licensing and regulatory services 20 
within the Department of Health and Human Services shall amend its rule Chapter 5:  21 
Regulatio ns for Licensing and Certifying of Substance Abuse Treatment Programs to 22 
permit outpatient opioid treatment providers to remain open 6 days per week rather than 7 23 
days per week.  24 
SUMMARY  25 
This bill directs the Department of Health and Human Services to amend  its rules to 26 
increase the MaineCare reimbursement rate for outpatient opioid treatment to $80 per 27 
week and to permit outpatient opioid treatment providers to be open 6 days per week as 28 
provided under federal law.  It directs the department to contract wit h a 3rd -party 29 
consultant to conduct a rate study regarding reimbursement to outpatient opioid treatment 30 
providers.  It authorizes opioid treatment programs under the Maine Pharmacy Act to 31 
operate without maintaining a pharmacist in charge but requires opio id treatment 32 
programs to enter into a written agreement with a licensed pharmacist to serve as a 33 
consultant to the opioid treatment program.  It authorizes registered professional nurses, 34 
certified nurse practitioners and licensed practical nurses to dispe nse opioid medication 35 
for substance abuse treatment purposes to patients in an opioid treatment program.  36 
 
